| アブストラクト | INTRODUCTION: The Janus kinase (JAK) inhibitors tofacitinib and baricitinib are new treatments for rheumatic diseases. Recent concerns regarding the risk of thrombosis have led to warnings by competent authorities. We therefore aimed to examine the thromboembolic safety signal for tofacitinib and baricitinib. METHODS: Individual case safety reports (ICSRs) for tofacitinib and baricitinib were retrieved from the World Health Organization global database VigiBase in April 2019. Primary outcomes were deep vein thrombosis (DVT) and pulmonary thrombosis (PT) or pulmonary embolism (PE). Patient demographics were summarized and then stratified by outcome. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs) worldwide, and stratified by either Europe or the US. RESULTS: In both the tofacitinib (n = 40,017) and baricitinib (n = 2138) ICSRs, patients with reported DVT or PT/PE were older and had higher reporting of prothrombotic medications or antithrombotic treatments, suggesting a pre-existing thromboembolic risk/event. In Europe, tofacitinib was associated with increased reporting for DVT (ROR 2.37, 95% CI 1.23-4.56) and PT/PE (ROR 2.38. 95% CI 1.45-3.89). For baricitinib, a threefold increased reporting odds was observed for DVT (ROR 3.47, 95% CI 2.18-5.52) and PT/PE (ROR 3.44, 95% CI 2.43-4.88) in Europe. In the US, tofacitinib was only associated with an elevated ROR of PT (ROR 2.05, 95% CI 1.45-2.90) and no baricitinib ICSRs were reported. CONCLUSION: This study supports the current recommendation for cautious use of tofacitinib in patients with high thromboembolic risk. Moreover, with a similar patient profile and elevated reporting for baricitinib, a potential class effect of JAK inhibitors cannot be ruled out. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2020/6/14 |
|---|
| 投稿者 | Vallejo-Yague, Enriqueta; Weiler, Stefan; Micheroli, Raphael; Burden, Andrea M |
|---|
| 組織名 | Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical;Sciences, ETH Zurich, Zurich, Switzerland.;National Poisons Information Centre, Tox Info Suisse, Associated Institute of the;University of Zurich, Zurich, Switzerland.;Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland.;Sciences, ETH Zurich, Zurich, Switzerland. andrea.burden@pharma.ethz.ch. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32533433/ |
|---|
